Portada Simposios - Supplements - Haematologica

XLII Reunión Nacional de la AEHH y XVI Congreso de la SETH. Simposios
215
42. Grancha S, Estellés A, Falcó C et al. Detailed localization of type 1 plasminogen
activator inhibitor mRNA expression and antigen in atherosclerotic
plaque on human coronary artery. Fibrinol Proteol 1998; 12: 53.
43. Estellés A, Tormo G, Gilabert J et al. Lipoprotein(a) levels and isoforms
and fibrinolytic activity in postmenopause. Influence of hormone replacement
therapy. Thromb Haemostas 1999; 81: 104.
44. Eriksson P, Kallin B, van’t Hooft FM et al. Allele-specific increase in basal
transcription of the plasminogen-activator inhibitor 1 gene is associated
with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851.
45. Margaglione M, Cappucci G, Colaizzo D et al. The PAI-1 gene locus
4G/5G polymorphism is associated with a family history of coronary
artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 152.
46. Ridker PM, Hennekens CH, Lindpaintner K et al. Arterial and venous thrombosis
is not associated with the 4G/5G polymorphism in the promoter
of the plasminogen activator inhibitor gene in a large cohort of
US men. Circulation 1997; 95: 59.
47. Grancha S, Estellés A, Tormo G et al. Plasminogen activator inhibitor-1
(PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating
levels in postmenopausal women with coronary artery disease. Influence
of hormone replacement therapy. Thromb Haemostas 1999;
81: 516.
48. Walsh BW, Kuller LH, Wild RA et al. Effects of raloxifene on serum lipids
and coagulation factors in healthy postmenopausal women. JAMA
1998; 18: 1445.